The phase I/II trials of the ‘Oxford vaccine’ (ChAdOx1) pointed to very high rates of mild side effects (~60%). Now, apparently a serious adverse event has occurred. https://t.co/VbZZRVLufL
— Prof Francois Balloux (@BallouxFrancois) September 8, 2020
